Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Roche"


25 mentions found


July 12 (Reuters) - Chip designer Nvidia (NVDA.O) will invest $50 million to speed up training of Recursion's (RXRX.O) artificial intelligence models for drug discovery, the companies said on Wednesday, sending the biotech firm's shares surging about 62%. Recursion, whose advisers include AI pioneer Yoshua Bengio, will use its biological and chemical datasets exceeding 23,000 terabytes to train AI models on Nvidia's cloud platform. Nvidia, seen as a big winner of the boom in artificial intelligence, could then license those models to biotech firms through BioNeMo, a generative AI cloud service for drug discovery that it rolled out earlier this year. The investment comes as Recursion strengthened its AI focus in May by snapping up two companies in the AI-driven drug discovery space for $87.5 million. The Salt Lake City, Utah-based company's current partners include Bayer (BAYGn.DE) and Roche (ROG.S).
Persons: Nvidia, Roche, Mubadala, Baillie Gifford, Chavi Mehta, Stephen Nellis, Mariam Sunny, Shilpi Majumdar, Sriraj Organizations: Nvidia, Bayer, Baillie Gifford & Co, Thomson Locations: BioNeMo, Salt Lake City , Utah, Abu, Bengaluru, San Francisco
Chipmaker Nvidia will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm's artificial intelligence models for drug discovery, the companies said Wednesday. AI models usually require vast amounts of data, typically measured in terabytes, to train them. Nvidia can then potentially license those AI models on BioNeMo, the company's cloud service for generative AI in drug discovery that it rolled out earlier this year. A month later, Google Cloud launched two new AI-powered tools that aim to help biotech and pharmaceutical companies accelerate drug discovery. The company in May acquired two companies in the AI-driven drug discovery space for $87.5 million.
Persons: Roche, Chris Gibson, Nvidia's, drugmakers, Exscientia, AbCellera Biologics, — CNBC's Benjamin Taubman Organizations: Nvidia, Pharmaceuticals, Bayer, NVIDIA, Moderna, Google Cloud Locations: Salt Lake City , Utah
Here’s What Buy Side Staffers Are Buying on Sale for Prime Day
  + stars: | 2023-07-11 | by ( ) www.wsj.com   time to read: +13 min
Here are products on sale that our team members are buying themselves—or already own and can highly recommend—during this year’s two-day Prime event. I’ve set goals to cook more than I eat out or order in to save money and for my health goals, so I’ll be purchasing this All-Clad cookware set this Prime Day for all my cooking needs. The 8-inch version is on sale for Prime Day, coming in at less than $300. Reviewers note that they’re ideal for larger hands.” —Leslie Yazel, editor, head of contentSalon-level styling tool“I bought the Revlon One Step Volumizer styling brush last Prime Day, and it has been a favorite all year. My partner always steals them when we travel, so this Prime Day, I’ll be buying him his own pair while they’re $100 off ahead of our fall wedding-season travels.” —Chao Li, head of product
Persons: what’s, juicer “ I’ve, , Nick Guy, I’ve, ” — Ian Salisbury, AirTag, Brittany Nguyen, Madeline Diamond, Emily Schwartzberg, It’s, ” — Emily Welsh, it’s, ” — Alix Milne, Rina Stone, I’ll, — Caroline Wernecke, Hydrating, — Irma Sahinovic, Astrid Stawiarz, ” — Leslie Yazel, Jessica Woodbury, I’d, Caroline Wernecke, ” — Bellamy Richardson, Bissell, ” — Chao Li Organizations: Side, Timex Men’s Expedition, Revlon, Altos, Colgate, Sony WH, 1000XM4, Sony Locations: France
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThis is the right kind of deal for this market, says GTCR Co-CEO Collin Rocheon on Worldpay dealCollin Roche, GTCR co-CEO, joins 'Closing Bell Overtime' to talk its purchase of Worldpay shares, the fintech market at large, and more.
Persons: GTCR, Collin Rocheon, Collin Roche
BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market. Foreign pharmaceuticals firms have struggled to cement any inroads they have made into the world's second-largest economy, with the government maintaining a drug procurement programme that forces them to slash their prices and refusing to approve the use of any foreign COVID-19 vaccines during the pandemic. But as China pursues home-grown modernisation it will also open up "more development opportunities for foreign-funded enterprises, including the pharmaceutical industry," Wang told the meeting. Wang told the meeting on Wednesday that his ministry will expand the channels of communication for responding to and solving concerns, with the meeting resulting in 25 specific suggestions to be taken forward. Reporting by Joe Cash; Additional reporting by Kevin Yao;Editing by Elaine HardcastleOur Standards: The Thomson Reuters Trust Principles.
Persons: Roche, Takeda, Wang Wentao, Wang, Li Qiang, Li, drugmakers, Joe Cash, Kevin Yao, Elaine Hardcastle Organizations: China's Commerce, AstraZeneca, Bayer, Merck, Novo Nordisk, Pfizer, Sanofi, Moderna, Wednesday, Economic, Thomson Locations: BEIJING, China, Tianjin
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDavid Roche: Bank of Japan will likely be pressured to take more 'dramatic' set of policy actionsDavid Roche, president of Independent Strategy, says Japan's central bank Governor Kazuo Ueda will be "forced to take a much more dramatic action down the road" due to elevated inflationary pressures in the economy.
Persons: David Roche, Kazuo Ueda Organizations: Bank of, Independent Locations: Bank of Japan
But officially colour-blind France has long refused to acknowledge any racial factor was at play. "From that point on, unions were involved in everything that's co-managed, including the managing of human resources," he told Reuters. But these fines are rare and rights groups say police officers often end up with light sentences, fuelling a sense of impunity. A rise in lethal police shootings over the last few years has been linked to a law reform in 2017, which broadens the circumstances in which an officer can use their firearm. "It is completely vague, and it allows to shoot much more freely," said Caille of the left-wing CGT police union.
Persons: Cedric Mas, Olivier Cahn, that's, " Cahn, Christophe Castaner, Gerald Darmanin, Franck Louvrier, Nicolas Sarkozy, Darmanin, Ravina Shamdasani, Anthony Caille, , Sebastian Roche, Michel Rose, Angus MacSwan Organizations: Rights, Twitter, Cergy University, Reuters, Socialists, United Nations, Police, CGT Police, of, Society, CGT, Thomson Locations: PARIS, Britain, France, United States, Paris, Moroccan, – France, U.S, Nice
It priced the one-time therapy, Roctavian, at $2.9 million. BioMarin said most study participants continued to respond to the gene therapy through year three and beyond, and it would continue to monitor them for 15 years. BioMarin's therapy will compete for market share with Roche's (ROG.S) Hemlibra, an antibody drug which mimics the function of the blood clotting protein missing in hemophilia A patients. In April, BioMarin cut its annual sales forecast range for Roctavian to $50 million to $100 million, from $100 million to $200 million. There are about 16,000 patients in the United States with hemophilia A in which they are missing the factor VIII clotting protein.
Persons: BioMarin, Joel Beatty, Robert W Baird, Roctavian, Beatty, Khushi Mandowara, Bhanvi Satija, Nathan Gomes, Akash Sriram, Deena Beasley, Krishna Chandra Eluri, Maju Samuel, David Gregorio Our Organizations: U.S . Food, Drug Administration, European Union, Los, Thomson Locations: U.S, California, Novato , California, hemophilia, United States, Bengaluru, Los Angeles
The pan-European STOXX 600 index (.STOXX) closed 0.7% higher, tracking overnight gains in Wall Street. Shares of Sage Group Plc (SGE.L) gained 5.1% to a 23-year high after J.P. Morgan upgraded its rating on the stock to "overweight" from "neutral". Shares of chip equipment maker ASML Holding (ASML.AS) rose 2.3% while Nordic Semiconductor (NOD.OL) jumped 6.4%, making technology (.SX8P) among the top European sectoral gainers. Semiconductor shares were in focus after a report stated the U.S. was considering new restrictions on exports of artificial intelligence chips to China. Also boosting the STOXX 600, Roche Holding (ROG.S) gained 1.5% after the U.S. health regulator declined to approve Regeneron's (REGN.O) Eylea drug.
Persons: Christine Lagarde, Jerome Powell, what's, Danni Hewson, AJ Bell, Morgan, Hewson, Roche, Morgan Stanley, Christian Klein, Matteo Allievi, Subhranshu Sahu, Sherry Jacob, Phillips, Alex Richardson Organizations: Sage Group, UBS, CS, . Federal, ASML, Nordic Semiconductor, Semiconductor, Carrefour, Credit Suisse, SAP, Thomson Locations: Wall, U.S, China, Swiss, Gdansk, Amruta, Bangalore
European shares rise as US data soothes economic slowdown fears
  + stars: | 2023-06-28 | by ( ) www.reuters.com   time to read: +1 min
June 28 (Reuters) - European shares climbed on Wednesday after robust U.S. data soothed concerns about a steep economic slowdown, while investors awaited commentary from central bankers at a forum later in the day for further policy direction. The pan-European STOXX 600 index (.STOXX) was up 0.5% by 0810 GMT, tracking Wall Street's gains overnight after data showed a rise in new orders for key U.S.-manufactured capital goods and heightened consumer confidence in June. Investors are keenly watching a panel discussion of central bankers in Sintra, including European Central Bank President Christine Lagarde, Federal Reserve Chair Jerome Powell and Bank of Japan Governor Kazuo Ueda. French supermarket chain Carrefour (CARR.PA) gained 3.1% after Morgan Stanley initiated coverage with an "overweight" rating. Reporting by Matteo Allievi in Gdansk and Amruta Khandekar in Bangalore; Editing by Subhranshu SahuOur Standards: The Thomson Reuters Trust Principles.
Persons: Christine Lagarde, Jerome Powell, Kazuo Ueda, Morgan Stanley, Matteo Allievi, Subhranshu Sahu Organizations: Roche, Investors, European Central Bank, Bank of Japan, Carrefour, Thomson Locations: Sintra, Gdansk, Amruta, Bangalore
A view of the Regeneron Pharmaceuticals headquarters in Tarrytown, New York. Shares of Regeneron fell nearly 9% Tuesday after the U.S. Food and Drug Administration declined to approve a higher-dose version of the company's blockbuster eye disease treatment. Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler." That suggests the drug could potentially win approval down the road. But a delay won't help the company fight off threats to its Eylea drug franchise, which is facing competition from Roche Holdings ' eye drug, Vabysmo.
Persons: Regeneron Organizations: Regeneron Pharmaceuticals, U.S . Food, Drug Administration, Roche Holdings Locations: Tarrytown , New York, U.S
The Food and Drug Administration cited an ongoing review of inspection findings at a third-party filler of the higher dose for the decision. Eylea, which recorded $9.65 billion in global sales last year, has been hit since Roche's (ROG.S) rival treatment Vabysmo was approved last year for wet AMD. Two late-stage trials had shown Eylea was as effective as the lower dose version when given at 8 milligrams at longer intervals without any additional safety issues. The two trials included treatment of patients with wet AMD and diabetic macular edema (DME). An estimated 1.1 million people in the U.S. have wet AMD, while 1.2 million are estimated to have DME, according to Regeneron.
Persons: Vabysmo, Regeneron, Eylea, Raghav Mahobe, Krishna Chandra Eluri, Maju Samuel, Sriraj Organizations: Regeneron Pharmaceuticals, Drug Administration, FDA, AMD, biosimilars, Thomson Locations: U.S, Bengaluru
CNN —Made by dragging fingers across relatively soft rock, lines, swirls and dots on the walls of a cave in France are the oldest known engravings by Neanderthals, according to a new analysis of the ancient marks. The finding adds to a growing body of evidence that Neanderthals — who have been characterized as dim-witted cave dwellers — were creative beings and more complex than the stereotype suggests. Neanderthals’ ‘deliberate composition’To understand how the markings were made and whether they were intentional, the researchers made detailed 3D models of the engravings from photographs of the Loire Valley’s La Roche-Cotard cave using a process known as photogrammetry. Based on the shape, spacing and arrangement of these engravings, the team concluded that markings in eight panels in La Roche-Cotard cave were intentional shapes and patterns created by human hands. At some cave sites in Spain, there’s evidence — albeit contentious — that Neanderthals created abstract motifs and hand stencils.
Persons: Jean, Claude Marquet, Cotard, La Roche, JC Marquet Organizations: CNN, University of Tours Locations: France, La Roche, Europe, Bulgaria, Spain
57,000-year-old engravings on the walls of a French cave may have been the work of Neanderthals. The oldest Neanderthal cave engravingsThe markings are made up of lines, squiggles, and dots, likely made by fingers instead of tools. On the left are some curved lines and on the right are more wavy lines that researchers say were made by Neanderthals. Tim Schoon, University of IowaThough early researchers considered Neanderthals less advanced than humans, more recent findings have complicated that view. In 2018, researchers estimated a group of Spanish cave paintings were 65,000 years old and made by Neanderthals.
Persons: , Claude Marquet, Shara Bailey, Homo sapiens, would've, Tim Schoon, It's, Bailey, sapiens, Cotard, lithics, La Organizations: Service, ONE, University of Tours, New York University, La Roche, University of Iowa Locations: France, La, Europe, Western Europe
Fed Chairman Jerome Powell testified before the House, central bank nominees are talking to the Senate, and the Washington Wizards traded away their star hooper. Powell spoke before the House Financial Services Committee yesterday following 10 consecutive interest rate hikes and one rate "skip" that the Fed chief made sure to clarify wasn't a "pause." "Given how far we've come, it may make sense to move rates higher but to do so at a more moderate pace," Powell said Wednesday. So far, the economy has been more resilient than expected, even as the fed funds rate hovers in the 5% to 5.25% range. US stock futures fall early Thursday, after Federal Reserve Chair Jerome Powell said more rate hikes are likely ahead.
Persons: I'm Phil Rosen, Jerome Powell, hooper, Anna Moneymaker, Powell, that's, Patrick McHenry, Tesla, Goldman Sachs, there's, Julia La Roche, Ed Yardeni, isn't, BofA's Savita Subramanian, Apple isn't, Read, Phil Rosen, Jason Ma, Hallam Bullock, Nathan Rennolds Organizations: Senate, Washington Wizards, Financial Services, Fed, Nvidia, Apple, Business, Federal, Accenture, Volex, Bank of America, . Locations: New York, Los Angeles, London
These 3 stocks are troubled but I'm not ready to give up
  + stars: | 2023-06-20 | by ( Jim Cramer | ) www.cnbc.com   time to read: +4 min
Johnson & Johnson (JNJ) is also a head-scratcher. EL YTD mountain Estee Lauder YTD performance Estee Lauder just shocks me. Estee Lauder, at the end of this week, acted like there was something going on, but I can't fathom what it might be. That said, there's a suit going on in Northern California with a dying 24-year-old man claiming that excess use of J & J baby powder is to blame, which could make $8.9 billion look small. Bottom line Johnson & Johnson, Estee Lauder and Danaher are why this business of stock picking and running a portfolio can be so daunting.
Persons: Estee Lauder, Johnson, Danaher's, Lauder, Houdini, Fabrizio Freda, Alex Gorsky, there's, Danaher, Jim Cramer's, Jim Cramer, Jim, Spencer Platt Organizations: CNBC, New York Stock Exchange, Getty Locations: Swiss, Roche, China, Cava, CAVA, Northern California, New York City
Joe Delich, a classmate who later worked with Mr. Roche at his law firm, remembers him constantly checking the price of Bitcoin on his laptop during classes. Mr. Roche cashed out before a big price drop, earning about $100,000 in profits. As a third-year student, Mr. Roche collaborated with a professor on a paper discussing Bitcoin’s virtues as the first currency free from government interference. By then, Mr. Roche was a first-year associate at Boies Schiller Flexner, where he was developing a reputation as the kid who understood crypto. But many people considered Dr. Wright a fraud, calling into question the notion that he had mined early blocks of Bitcoin, much less cheated someone out of them.
Persons: Joe Delich, Roche, , Boies Schiller, Ira Kleiman, Craig Wright, Satoshi Nakamoto, Kleiman, Wright, David, David Kleiman Organizations: Purdue University, Northwestern University’s Pritzker School of Law, Mr, Street Locations: Miami
Folarin Balogun recently committed to representing the United States men’s national team (USMNT), ending years of speculation about whether the 21-year-old would choose to play for the US or England on the international stage. Here’s all you need to know about the prodigious striker ahead of his potential USMNT debut against Mexico. Stu Forster/Getty ImagesOn the pitch, Balogun has refined his game over the past two seasons. After the Arsenal man’s haul last season, Barker also believes this could be just the beginning for the striker. “I’m not sure he will be an elite, world class player,” Barker said, “but you certainly wouldn’t bet against him.”
Persons: Lionel Messi, Ballon d’Or, Folarin Balogun, Gregg Berhalter’s, Jesus Ferreira, Josh Sargent, Haji Wright, , James Williamson, Flo, unforthcoming, Balogun, Art de, Charles McQuillan, ” de Roché, it’s, Roché, de Roché, he’s, Stu Forster, “ He’s, , Alex Barker, ” Barker, Oliver Giroud, Roberto Firmino, Messi, Germain, Francois Nascimbeni, Balogun’s, Barker, John Dorton, who’s, that’ll, De Roché, Xavier Laine, “ I’m Organizations: CNN, Inter Miami, France’s Ligue, United, United States men’s national, Mexico, Arsenal, Premier League club’s, Middlesbrough, Ligue, Reims, CNN Sport, Millwall, Stade Vélodrome, Marseille, West Brom, EFL Championship, Twitter, , Paris Saint, , Getty, USSF, US, USSF ‘ Locations: USA, Argentine, Brooklyn, United States, England, Qatar, Netherlands, New York, Millwall’s, Reims, Ligue, AFP, Canada, Mexico, France
June 12 (Reuters) - Novartis (NOVN.S) said it has agreed to acquire U.S. biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. The other drug hopeful is iptacopan, which is being trialled against a number of rare genetic disorders, including IgAN and another kidney disease. IgAN is a progressive autoimmune disease that mostly affects young adults and which can lead to kidney failure that requires dialysis or organ transplantation. IgAN is the most common cause of kidney failure in Caucasian young adults, Novartis added. Additional reporting by Miranda Murray; Editing by Kim Coghill, Sonali Paul and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
Persons: Novartis, Vas Narasimhan, Narasimham, atrasentan, Narasimhan, Kisqali, Roche, Vera, Muddy Waters, Miranda Murray, Kim Coghill, Sonali Paul, Alexander Smith Organizations: Novartis, Chinook Therapeutics, Vera Therapeutics, Sandoz, Chinook, Thomson Locations: Seattle, United States
Nine global stocks have raised dividends every year for the past three decades, according to CNBC Pro analysis. Of about 92,000 global stocks screened by CNBC Pro, the following nine consistently rewarded their shareholders. Novartis' stock has been on an upward trend recently – rising 8.9% year to date – after moving sideways for more than six months. Novartis' dividend yield is currently 3.5%. NOVNEE-CH 1Y line Roche Like its peer Novartis, Roche , the pharmaceuticals and diagnostics company headquartered in Basel, Switzerland, offers a 3.3% dividend yield.
Persons: Maurice Choy, . Choy, Eric Le Berrigaud, Roche, Luisa Hector, James Halstead Organizations: CNBC, CNBC Pro, Fortis Canadian, Fortis, RBC Capital, Novartis, Roche, Pharma, Sage Group, Kerry Locations: Novartis Swiss, Basel, Switzerland, ROG, Spirax, Saco
The hope is for "a completely new treatment paradigm in cancer that will be better tolerated and unique to individual patients' tumors," said Dr. Jane Healy, an executive overseeing in early cancer treatment development at Merck. The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. Aiming at these unique proteins allows the immune system to kill cancer cells while leaving healthy tissue unscathed. With standard treatment, 90% of pancreatic cancer patients die within five years of diagnosis. The approach first primes the immune system with an older technology called a chimpanzee adenovirus vaccine that targets patients' tumors.
Persons: Andrew Kelly, Keytruda, Jane Healy, Germany's BioNTech, Vinod Balachandran, we've, we're, Andrew Allen, Healy, Julie Steenhuysen, Caroline Humer, Bill Berkrot Organizations: Merck & Co, REUTERS, CHICAGO, Moderna Inc, American Society of Clinical Oncology, Merck, Moderna, Memorial Sloan Kettering Cancer Center, Thomson Locations: Kenilworth , New Jersey, U.S, Chicago, New York, Nature
Indivior opioid settlement makes purer M&A case
  + stars: | 2023-06-05 | by ( ) www.reuters.com   time to read: +2 min
LONDON, June 5 (Reuters Breakingviews) - Indivior (INDV.L) is one step closer to becoming a takeover target. Litigation risks have weighed down Indivior in the years following the company’s spinoff from Reckitt Benckiser (RKT.L) in 2014. The group still has lawsuits to settle over the same charges with insurers and patients. With its litigation risks easing, Indivior could soon lure larger cash rich pharmaceutical companies keen to access a market that is sadly showing no signs of decline. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Persons: Reckitt, Roche, Indivior, Aimee Donnellan, Neil Unmack, Streisand Neto Organizations: Reuters, Suboxone, AstraZeneca, U.S . Centers for Disease Control, Twitter, Toyota, Thomson Locations: U.S
Speaker McCarthy discussed the latest development of the debt ceiling negotiations with the White House. (Photo by Win McNamee/Getty Images) Win Mcnamee | Getty Images News | Getty ImagesAnalysts are broadly optimistic that the deal to raise the U.S. debt ceiling will pass a divided Congress. The compromise also sees the debt ceiling suspended until Jan. 1, 2025, pushing it past the 2024 presidential election. watch nowDavid Roche, president and global strategist for Independent Strategy saw this as a "Democratic win." He expects the deal will pass the House with Democratic support, although, like Pavlick, he said right-wing Republicans will likely vote against it.
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailU.S. debt ceiling deal is a 'democratic victory,' says David RocheDavid Roche of Independent Strategy says the deal will allow borrowing to "go forward well into 2024," among other things.
A New Yorker thought she found her "dream couch" on the side of the road, so she brought it home. Her video documenting the find garnered over 30 million views as users weighed in on the couch worth up to $8,000. While some praised Joy for the find, others raised concerns of bed bugs and its authenticity. Others were more concerned about the risk of bed bugs and mold after Joy said the couch had been rained on when she found it. "Getting rid of bed bugs can cost thousands of dollars."
Total: 25